$0.28 EPS Expected for Neo Performance Materials Inc. (NEO); Exact Sciences (EXAS) Shorts Decreased By 10.54%

April 17, 2018 - By Adrian Mccoy

Exact Sciences Corporation (NASDAQ:EXAS) Logo

Analysts expect Neo Performance Materials Inc. (TSE:NEO) to report $0.28 EPS on May, 14 before the open.T_NEO’s profit would be $11.18M giving it 15.80 P/E if the $0.28 EPS is correct. After having $0.28 EPS previously, Neo Performance Materials Inc.’s analysts see 0.00% EPS growth. The stock decreased 0.28% or $0.05 during the last trading session, reaching $17.7. About 2,800 shares traded. Neo Performance Materials Inc. (TSE:NEO) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Exact Sciences Corporation (NASDAQ:EXAS) had a decrease of 10.54% in short interest. EXAS’s SI was 14.16M shares in April as released by FINRA. Its down 10.54% from 15.83M shares previously. With 2.51 million avg volume, 6 days are for Exact Sciences Corporation (NASDAQ:EXAS)’s short sellers to cover EXAS’s short positions. The SI to Exact Sciences Corporation’s float is 12.11%. The stock increased 6.24% or $2.8 during the last trading session, reaching $47.68. About 2.74 million shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 81.43% since April 17, 2017 and is uptrending. It has outperformed by 69.88% the S&P500.

Neo Performance Materials Inc., through its subsidiaries, engages in manufacturing rare earth- and rare metal functional materials in Japan, China, Thailand, Estonia, Singapore, Germany, United Kingdom, Canada, United States, and South Korea. The company has market cap of $706.61 million. It offers rare earth magnetic powders for bonded and hot deformed fully dense NdFeB magnets for automotive motors, traction motors, micro motors, and sensors, as well as engages in the separation and processing of rare earth concentrate into functional materials for auto catalysts, consumer electronics, magnets, and wastewater treatment; and production, reclamation, refine, and marketing of rare metals and their compounds that include tantalum, niobium, gallium, hafnium, rhenium, and indium for jet engines, medical imaging, wireless technologies, and LED lighting. It has a 29.02 P/E ratio.

Since January 2, 2018, it had 0 buys, and 20 insider sales for $24.73 million activity. Another trade for 2,122 shares valued at $85,124 was sold by COWARD D SCOTT. $6.62M worth of Exact Sciences Corporation (NASDAQ:EXAS) shares were sold by Conroy Kevin T. The insider ARORA MANEESH sold $243,068. Another trade for 7,232 shares valued at $325,440 was sold by Zanotti Katherine S. Another trade for 27,428 shares valued at $1.11 million was sold by LIDGARD GRAHAM PETER. On Friday, February 23 Elliott Jeffrey Thomas sold $126,252 worth of Exact Sciences Corporation (NASDAQ:EXAS) or 2,982 shares. On Tuesday, April 10 Carey Thomas D. sold $335,630 worth of Exact Sciences Corporation (NASDAQ:EXAS) or 8,448 shares.

Among 18 analysts covering EXACT Sciences (NASDAQ:EXAS), 11 have Buy rating, 1 Sell and 6 Hold. Therefore 61% are positive. EXACT Sciences had 74 analyst reports since July 24, 2015 according to SRatingsIntel. Roth Capital maintained Exact Sciences Corporation (NASDAQ:EXAS) rating on Friday, October 30. Roth Capital has “Buy” rating and $12 target. The firm has “Outperform” rating given on Thursday, September 21 by Leerink Swann. The firm earned “Hold” rating on Friday, February 23 by Benchmark. The rating was maintained by Craig Hallum with “Buy” on Wednesday, July 26. The company was maintained on Friday, February 23 by Stephens. The company was maintained on Tuesday, October 6 by TH Capital. BTIG Research initiated it with “Buy” rating and $14 target in Friday, December 18 report. The firm has “Buy” rating given on Wednesday, May 31 by Cowen & Co. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, June 7 report. Benchmark maintained Exact Sciences Corporation (NASDAQ:EXAS) on Wednesday, January 17 with “Buy” rating.

Investors sentiment decreased to 0.88 in Q4 2017. Its down 0.13, from 1.01 in 2017Q3. It dropped, as 25 investors sold Exact Sciences Corporation shares while 105 reduced holdings. 44 funds opened positions while 70 raised stakes. 92.48 million shares or 1.24% less from 93.65 million shares in 2017Q3 were reported. Granahan Inv Management Inc Ma owns 208,070 shares. Envestnet Asset Mgmt Incorporated invested 0% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Massmutual Fsb Adv has 47 shares for 0% of their portfolio. Massachusetts Financial Ma accumulated 175,315 shares. 42,481 were reported by Stevens Capital Management L P. Amalgamated Bancshares has 0.02% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 15,998 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 7,137 shares. Dupont Cap holds 22,279 shares or 0.03% of its portfolio. Parkside Bancorporation holds 0% or 55 shares. Antipodean Lc has invested 24.63% in Exact Sciences Corporation (NASDAQ:EXAS). Shelton Capital Mgmt holds 8,800 shares or 0.03% of its portfolio. Goldman Sachs Gp Incorporated reported 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Tiverton Asset Management Ltd Liability Co invested in 222,818 shares or 0.73% of the stock. Fred Alger Management holds 0.42% or 1.77M shares in its portfolio. Frontier Cap Limited Com accumulated 892,079 shares.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $5.77 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts